Logo do repositório
 
Publicação

Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023)

2025-01-25Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorSavulescu, Camelia
dc.contributor.authorPrats-Uribe, Albert
dc.contributor.authorBrolin, Kim
dc.contributor.authorUusküla, Anneli
dc.contributor.authorBergin, Colm
dc.contributor.authorFleming, Catherine
dc.contributor.authorZvirbulis, Viesturs
dc.contributor.authorZavadska, Dace
dc.contributor.authorSzułdrzyński, Konstanty
dc.contributor.authorGaio, Vânia
dc.contributor.authorPopescu, Corneliu Petru
dc.contributor.authorCraiu, Mihai
dc.contributor.authorCisneros, Maria
dc.contributor.authorLatorre-Millán, Miriam
dc.contributor.authorLohur, Liis
dc.contributor.authorMcGrath, Jonathan
dc.contributor.authorFerguson, Lauren
dc.contributor.authorAbolina, Ilze
dc.contributor.authorGravele, Dagne
dc.contributor.authorMachado, Ausenda
dc.contributor.authorFlorescu, Simin Aysel
dc.contributor.authorLazar, Mihaela
dc.contributor.authorSubirats, Pilar
dc.contributor.authorClusa Cuesta, Laura
dc.contributor.authorSui, Jacklyn
dc.contributor.authorKenny, Claire
dc.contributor.authorKrievins, Dainis
dc.contributor.authorBarzdina, Elza Anna
dc.contributor.authorMelo, Aryse
dc.contributor.authorKosa, Alma Gabriela
dc.contributor.authorMiron, Victor Daniel
dc.contributor.authorMuñoz-Almagro, Carmen
dc.contributor.authorMilagro, Ana María
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKramarz, Piotr
dc.contributor.authorNardone, Anthony
dc.contributor.authorVEBIS HCW Study Group
dc.date.accessioned2026-02-19T16:04:12Z
dc.date.available2026-02-19T16:04:12Z
dc.date.issued2025-01-25
dc.descriptionVEBIS HCWVEStudy Group - Portugal: Ana Palmira Amaral, Raquel Guiomar, Camila Henriques, Daniela Dias, Licínia Gomes, Miguel Lança, Ana João Santos.
dc.description.abstractIntroduction: Repeated COVID-19 booster vaccination was recommended in healthcare workers (HCWs) to maintain protection. We measured the relative vaccine effectiveness (rVE) of the second booster dose of COVID-19 vaccine compared to the first booster, against laboratory-confirmed SARS-CoV-2 infection in HCWs. Methods: In a prospective cohort study among HCWs from 12 European hospitals, we collected nasopharyngeal or saliva samples at enrolment and during weekly/fortnightly follow-up between October 2022 and May 2023. We estimated rVE of the second versus first COVID-19 vaccine booster dose against SARS-CoV-2 infection, overall, by time since second booster and restricted to the bivalent vaccines only. Using Cox regression, we calculated the rVE as (1-hazard ratio)*100, adjusting for hospital, age, sex, prior SARS-CoV-2 infection and at least one underlying condition. Results: Among the 979 included HCWs eligible for a second booster vaccination, 392 (40 %) received it and 192 (20 %) presented an infection during the study period. The rVE of the second versus first booster dose was -5 % (95 %CI: -46; 25) overall, 3 % (-46; 36) in the 7-89 days after receiving the second booster dose. The rVE was 11 % (-43; 45) when restricted to the use of bivalent vaccines only. Conclusion: The bivalent COVID-19 could have reduced the risk of SARS-CoV-2 infection among HCWs by 11 %. However, we note the limitation of imprecise rVE estimates due to the proportion of monovalent vaccine used in the study, the small sample size and the study being conducted during the predominant circulation of XBB.1.5 sub-lineage. COVID-19 vaccine effectiveness studies in HCWs can provide important evidence to inform the optimal timing and the use of updated COVID-19 vaccines.eng
dc.description.sponsorshipThis study was funded by European Centre for Disease Prevention and Control through “Vaccine Effectiveness, Burden and Impact Studies” (VEBIS) Lot 2 “Assessment of COVID-19 and influenza vaccine effectiveness among healthcare workers” framework contract ECDC/2021/017.
dc.identifier.citationVaccine. 2025 Jan 25:45:126615. doi: 10.1016/j.vaccine.2024.126615. Epub 2024 Dec 25
dc.identifier.doi10.1016/j.vaccine.2024.126615
dc.identifier.issn0264-410X
dc.identifier.pmid39724693
dc.identifier.urihttp://hdl.handle.net/10400.18/10953
dc.language.isoen
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S0264410X24012970?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCOVID-19
dc.subjectCOVID-19 vaccines
dc.subjectSARS-CoV-2
dc.subjectHealthcare Workers
dc.subjectVaccine Effectiveness
dc.subjectEurope
dc.subjectInfecções Respiratórias
dc.subjectEstados de Saúde e de Doença
dc.titleRelative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023)eng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage126615
oaire.citation.titleVaccine
oaire.citation.volume45
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
1-s2.0-S0264410X24012970-main.pdf
Tamanho:
811.83 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DDI - Artigos em revistas internacionais
DEP - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais